Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
MGX
Upturn stock ratingUpturn stock rating

Metagenomi, Inc. Common Stock (MGX)

Upturn stock ratingUpturn stock rating
$1.82
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

09/15/2025: MGX (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

7 Analysts rated it

Limited analyst coverage, niche firm, research info may be scarce.

1 Year Target Price $9.5

1 Year Target Price $9.5

Analysts Price Target For last 52 week
$9.5 Target price
52w Low $1.23
Current$1.82
52w High $4.92

Analysis of Past Performance

Type Stock
Historic Profit -13.12%
Avg. Invested days 27
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 1.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 09/15/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 69.81M USD
Price to earnings Ratio -
1Y Target Price 9.5
Price to earnings Ratio -
1Y Target Price 9.5
Volume (30-day avg) 7
Beta -
52 Weeks Range 1.23 - 4.92
Updated Date 09/15/2025
52 Weeks Range 1.23 - 4.92
Updated Date 09/15/2025
Dividends yield (FY) -
Basic EPS (TTM) -2.33

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -257.99%
Operating Margin (TTM) -246.53%

Management Effectiveness

Return on Assets (TTM) -17.44%
Return on Equity (TTM) -37.45%

Valuation

Trailing PE -
Forward PE -
Enterprise Value -92191368
Price to Sales(TTM) 2.07
Enterprise Value -92191368
Price to Sales(TTM) 2.07
Enterprise Value to Revenue -
Enterprise Value to EBITDA -
Shares Outstanding 37533100
Shares Floating 25276690
Shares Outstanding 37533100
Shares Floating 25276690
Percent Insiders 28.09
Percent Institutions 19.3

ai summary icon Upturn AI SWOT

Metagenomi, Inc. Common Stock

stock logo

Company Overview

overview logo History and Background

Metagenomi, Inc. is a gene editing company focused on discovering and developing novel CRISPR-based technologies. Founded in 2018, it leverages metagenomics to identify and engineer new gene editing systems with improved efficacy and safety profiles. The company went public in February 2024.

business area logo Core Business Areas

  • Therapeutic Development: Developing gene editing therapies for a range of genetic diseases, including liver, lung, and central nervous system disorders.
  • Platform Discovery: Identifying and characterizing novel CRISPR-based gene editing systems from diverse environmental sources through metagenomics.
  • Technology Licensing: Licensing its gene editing technology platform to other companies for therapeutic and research applications.

leadership logo Leadership and Structure

Brian C. Thomas is the co-founder and CEO. The company has a board of directors with expertise in biotechnology, finance, and drug development. The organizational structure is typical of a biotech company, with departments focused on research, development, clinical trials, and business operations.

Top Products and Market Share

overview logo Key Offerings

  • MGON-DTLA: A lead preclinical program targeting a specific rare genetic disorder. Data is currently unavailable about market share or revenue at this time. Key competitors are companies developing similar gene editing therapies, such as Editas Medicine, Beam Therapeutics, and Intellia Therapeutics.
  • CRISPR Discovery Platform: A proprietary metagenomics-based platform for identifying novel CRISPR systems. Revenue is generated through licensing agreements and partnerships. The platform competes with other gene editing technology platforms, like those offered by Caribou Biosciences and Mammoth Biosciences.

Market Dynamics

industry overview logo Industry Overview

The gene editing industry is rapidly growing, driven by advances in CRISPR technology and increasing demand for therapies for genetic diseases. The market is highly competitive, with many companies developing gene editing tools and therapies.

Positioning

Metagenomi is positioned as a leader in the discovery of novel CRISPR systems. Its metagenomics approach provides a unique advantage in identifying diverse and potentially more effective gene editing tools.

Total Addressable Market (TAM)

The gene editing market is expected to reach hundreds of billions of dollars in the coming years. Metagenomi is positioned to capture a significant share of this market with its innovative technology platform.

Upturn SWOT Analysis

Strengths

  • Novel CRISPR discovery platform
  • Strong intellectual property portfolio
  • Experienced management team
  • Potential for partnerships and licensing agreements

Weaknesses

  • Early-stage company with limited clinical data
  • High research and development costs
  • Dependence on key partnerships
  • Risk of competition from larger companies

Opportunities

  • Expanding into new therapeutic areas
  • Developing partnerships with pharmaceutical companies
  • Securing regulatory approvals for gene editing therapies
  • Capitalizing on the growing demand for gene editing technologies

Threats

  • Competition from established gene editing companies
  • Regulatory hurdles and uncertainties
  • Potential safety concerns with gene editing therapies
  • Ethical concerns surrounding gene editing

Competitors and Market Share

competitor logo Key Competitors

  • CRSP
  • EDIT
  • BEAM

Competitive Landscape

Metagenomi competes with established gene editing companies like CRISPR Therapeutics, Editas Medicine, and Beam Therapeutics. Its advantage lies in its novel CRISPR discovery platform. However, it faces the challenges of being a smaller company with limited clinical data.

Growth Trajectory and Initiatives

Historical Growth: Limited historical growth data is available due to the company's early stage. The IPO represented a major milestone in the company's growth.

Future Projections: Future growth is dependent on the successful development and commercialization of its gene editing therapies. Analyst estimates vary but generally project significant revenue growth in the coming years.

Recent Initiatives: Recent initiatives include advancing preclinical programs, expanding the CRISPR discovery platform, and establishing partnerships with pharmaceutical companies.

Summary

Metagenomi is an early-stage gene editing company with a unique technology platform. Its novel CRISPR discovery approach provides a competitive advantage. However, it faces risks associated with drug development and competition from larger companies. The company needs to successfully advance its clinical programs and secure partnerships to achieve its growth potential.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Metagenomi, Inc. Investor Relations
  • SEC Filings (10-K, 10-Q)
  • Company Press Releases
  • Analyst Reports
  • Market Research Reports

Disclaimers:

This analysis is for informational purposes only and should not be considered investment advice. Market share data is based on estimates and may not be precise. Future performance is not guaranteed.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Metagenomi, Inc. Common Stock

Exchange NASDAQ
Headquaters EmeryVille, CA, United States
IPO Launch date 2024-02-09
Co-Founder, CEO & Chairman of the Board Dr. Brian Charles Thomas Ph.D.
Sector Healthcare
Industry Biotechnology
Full time employees 171
Full time employees 171

Metagenomi, Inc., a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. Its genome editing toolbox includes nuclease-based genome editing, base editors, RNA-mediated integration, including prime editing, and DNA-mediated integration, such CRISPR-associated transposases. The company has a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop and commercialize investigational medicines using genome editing technologies; and a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited TCR-based therapeutic products exclusively in the field of treatment, prevention, or diagnosis of any human cancer. Metagenomi, Inc. was incorporated in 2016 and is headquartered in Emeryville, California.